Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Katarina Zanchetta"'
Autor:
Patrik Palacka, Monika Polanova, Alena Svobodova, Jan Zigmond, Katarina Zanchetta, Vlasta Gombarova, Martina Vulganova, Jan Slopovsky, Jana Obertova, Michal Mego, Lubos Drgona, Juraj Pechan
Publikováno v:
Journal of Clinical Oncology. 40:e18774-e18774
e18774 Background: Vaccination remains the leading strategy against Covid-19 worldwide. BNT 162b2 (tozinameran) belongs among first licensed vaccines with good efficacy. However, the role of monitoring both, antibodies and cell immunity after vaccina
Autor:
Michal Mego, Katarina Zanchetta, Juraj Pechan, Vladimira Baranova, Jan Slopovsky, Beata Bernadicova, Eva Badurikova, Lubos Drgona, Patrik Palacka
Publikováno v:
Journal of Clinical Oncology. 39:e18724-e18724
e18724 Background: Active immunization seems to be the most effective protection against COVID-19. The objective of this prospective study was to explore the side effects of mRNA vaccine Tozinameran and possible differences in their incidence between
Autor:
Patrik Palacka, Monika Pol’anová, Alena Svobodová, Jan Žigmond, Katarína Zanchetta, Vlasta Gombárová, Martina Vulganová, Ján Slopovský, Jana Obertová, Ľuboš Drgoňa, Michal Mego, Juraj Pechan
Publikováno v:
Vaccines, Vol 10, Iss 4, p 558 (2022)
Vaccination remains the leading strategy against COVID-19 worldwide. BNT162b2 is among the first licensed vaccines with high effectiveness. However, the role of antibody and cell immunity response monitoring after vaccination remains unclear. We cond
Externí odkaz:
https://doaj.org/article/34779625ae434ebd84a5f67ca6cde37c